

# United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FII	LING DATE .	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/726,878	378 12/02/2003		Charles Price Taylor JR.	PC26098A	5420	
28523	7590	03/24/2006		EXAM	EXAMINER	
PFIZER IN		NT M00000 10	GRAFFEO, MICHEL			
EASTERN I		ENT, MS8260-161 AD	ART UNIT	PAPER NUMBER		
GROTON,	CT 06340	)	1614	· •		

DATE MAILED: 03/24/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)					
Office Action Community	10/726,878	TAYLOR ET AL.					
Office Action Summary	Examiner	Art Unit					
	Michel Graffeo	1614					
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the c	orrespondence address					
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA  - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication.  - If NO period for reply is specified above, the maximum statutory period w  - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION  16(a). In no event, however, may a reply be tim  ill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	J. nely filed the mailing date of this communication. D (35 U.S.C. § 133).					
Status							
1) Responsive to communication(s) filed on							
	-· action is non-final.						
· <u> </u>	· <del></del>						
<i>,</i> —	closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.						
Disposition of Claims	•						
4) Claim(s) 1-16 is/are pending in the application.							
4a) Of the above claim(s) is/are withdrawn from consideration.							
5) Claim(s) is/are allowed.							
6) Claim(s) is/are rejected.							
· · · · · · · · · · · · · · · · · · ·	') Claim(s) is/are objected to. S) Claim(s) <u>1-16</u> are subject to restriction and/or election requirement.						
of the state of th	icodon requirement.						
Application Papers							
9) The specification is objected to by the Examiner							
10) The drawing(s) filed on is/are: a) acce	epted or b) $\square$ objected to by the E	Examiner.					
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).							
Replacement drawing sheet(s) including the correcti	on is required if the drawing(s) is obj	ected to. See 37 CFR 1.121(d).					
11) The oath or declaration is objected to by the Exa	aminer. Note the attached Office	Action or form PTO-152.					
Priority under 35 U.S.C. § 119							
12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of:	,	-(d) or (f).					
1. Certified copies of the priority documents have been received.							
<ul> <li>2. Certified copies of the priority documents have been received in Application No</li> <li>3. Copies of the certified copies of the priority documents have been received in this National Stage</li> </ul>							
							application from the International Bureau (PCT Rule 17.2(a)).  * See the attached detailed Office action for a list of the certified copies not received.
See the attached detailed Office action for a list of	or the certified copies not receive	a.					
Attachment(s)	,, <del>[m]</del> , , , ,						
1)	4) Interview Summary Paper No(s)/Mail Da						
3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)	5) 🔲 Notice of Informal P	atent Application (PTO-152)					
Paper No(s)/Mail Date	6)  Other:						

### **DETAILED ACTION**

#### Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- Claims 2-9 and 13-16, drawn to a method of treating premature ejaculation, classified in class 514, subclass 724.
- II. Claims 11-12, drawn to a composition comprising an alpha-2-delta ligand, classified in class 514, subclass 740.

Inventions I and II are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the product can be used for the treatment of LUTS.

In addition, if Applicant elects Group I <u>Applicant is required</u> to make an election of one species therein as discussed below.

The practice, re: Markush claims encompassing multiple independent and patentably distinct inventions is set for the in M.P.E.P. 803. The following requirement to make a provisional election of a <u>single independent and patentably distinct invention</u> is made pursuant to said practice.

Application/Control Number: 10/726,878

Art Unit: 1614

Claim 1 for example, is drawn in Markush format encompass multiple and patentably distinct inventions. The claims are either drawn to alpha-2-delta ligands having classifiably different core structures.

Invention 1: the compounds of formulas I and XXXIII in class 514 subclass 724

Invention 2: the compounds of formulas II, XXX, XXI and XXXII in class 514 subclass 740

Invention 3: the compounds of formulas III, IV in class 514 subclass 210

Invention 4: the compounds of formulas V-X in class 514 subclass 766

Invention 5: the compounds of formulas XI-XXVII in class 514 subclass 210

Invention 6: the compound of formula XXVIII in class 514 subclass 359

Invention 7: the compound of formula XXIX in class 514 subclass 381

Invention 8: the compounds of formulas XXXIV-XXXVII in class 514 subclass 762

Invention 9: the compounds of formula XXXVIII in class 514 subclass 724

Invention 10: the compounds of formula XXXIX in class 514 subclass 740

The groups above are set forth in order of precedence in the claims. Any specie/compound/composition having the distinguishing feature set forth in one of the above groups will be contained in that group regardless of the fact that it may also contain a feature set forth in a group of lower precedence.

It is considered that at Markush type claim encompassing such species is directed to multiple independent and patentably distinct inventions since the species are so unrelated and diverse that a prior art reference anticipating the claims with respect to one of the species will not render the claim anticipated or obvious under 35 U.S.C. 102 nor 35 U.S.C. 103 respectively with regard to any one other of the species. Further these species are considered to be independent since they are unconnected in operation, one does not require the others for ultimate use and the specification does not disclose a dependent relationship between them. Moreover, each of the stated species is considered patentably distinct from the others on the basis of its properties. Thus, the stated species are capable of supporting separate patents under 35 U.S.C. 121.

Accordingly, <u>applicants are required</u> to make a provisional election of a single independent and /or patentably distinct Invention stated *supra* prior to an examination of said species on the merits.

## **Election of Species**

Applicant is required under 35 U.S.C. 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Specifically, applicant is required to define each of R<sup>1</sup>, R<sup>2</sup> and any additional variables as required for a particular species. Currently, claim 1 is generic.

Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

## Election/Restrictions Proper

MPEP §809.02(d) states "[w]here only generic claims are presented, no restriction can be required except in those applications where the generic claims recite such a multiplicity of species that an unduly extensive and burdensome search is necessary.". Here, the claims recited such a multiplicity of species that an unduly extensive and burdensome search would be necessary if all of the claimed species were to be examined simultaneously.

The present claims are directed to a method of treating respiratory complaints.

Present claim 1 for example provides a variety of possibilities for R<sup>1</sup> and R<sup>2</sup>. For hypothetical exemplification purposes only, if each of the variables above were each limited to 10 possible moieties there would be 10<sup>2</sup> possible species of compounds to be searched.

Further, as shown by the following classifications, a majority of the combinations encompassed by the present claims has acquired a separate status in the art. For example, -C-O- groups are classified in class 514 subclass 724 whereas N containing compounds are classified in class 514 subclass 740. Notwithstanding that the classification of some of the active agents is co-extensive, all of the claimed compounds are patently distinct and fully capable of supporting separate patents.

For the above reasons, an election of a single disclosed species for examination purposes is deemed necessary and proper.

Application/Control Number: 10/726,878

Art Unit: 1614

Conclusion

Page 7

Any inquiry concerning this communication or earlier communications from the

examiner should be directed to Examiner Graffeo whose telephone number is 571-272-

8505. The examiner can normally be reached on 9am to 5:30pm Monday to Friday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's

supervisor, Christopher Low can be reached on 571-272-0951. The fax phone number

for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the

Patent Application Information Retrieval (PAIR) system. Status information for

published applications may be obtained from either Private PAIR or Public PAIR.

Status information for unpublished applications is available through Private PAIR only.

For more information about the PAIR system, see http://pair-direct.uspto.gov. Should

you have questions on access to the Private PAIR system, contact the Electronic

Business Center (EBC) at 866-217-9197 (toll-free).

19 March 2006

MG